Neuroprotection in the SAINT-II aftermath [4]

Annals of Neurology

Volumn 62, Issue 6, 2007, Pages 677-678

  Hermann, Dirk M ^a   Bassetti, Claudio L ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DISUFENTON SODIUM; NEUROPROTECTIVE AGENT;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LETTER; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME;

BENZENESULFONATES; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; HUMANS; NEUROPROTECTIVE AGENTS; SPIN TRAPPING; STROKE;

EID: 36448933286     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21210     Document Type: Letter

References (5)

1. Savitz SI, Fisher M. Future of neuroprotection in the aftermath of the SAINT trials. Ann Neurol 2007;61:396-402.
2. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U. SAINT II Trial Investigators. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007;357:562-571.
3. Lees KR, Zivin JA, Ashwood T, et al, Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med 2006;354:588-600.
4. Stroke Therapy Academic Industry Roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752-2758.
5. Hermann DM, Bassetti CL. Implications of ATP-binding cassette transporters for brain pharmacotherapies. Trends Pharmacol Sci 2007;28:128-134.